PIK3CB and neoplasm: In this context, the PI3K/mTOR pathway has emerged as a central regulator of the tumour microenvironment (TME) and recent investigations have unveiled its potential contribution to ICB‐resistance in some epithelial tumour types, such as breast and colorectal cancer.8